Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison the Safety and Efficacy of Epirubicin Plus Cyclophosphamide (EC)Versus Docetaxel Plus Cyclophosphamide (TC) in Lymph Node Negative, ER Positive, Her2 Negative Breast Cancer Patients as Adjuvant Chemotherapy

NCT02549677 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT02549677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02549677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison the Safety and Efficacy of Epirubicin Plus Cyclophosphamide (EC)Versus Docetaxel Plus Cyclophosphamide (TC) in Lymph Node Negative, ER Positive, Her2 Negative Breast Cancer Patients as Adjuvant Chemotherapy
Lead sponsor
Ruijin Hospital
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2015
Completion date
March 31, 2020
Enrollment
294 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms